Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan
· Delayed Price · Currency is TWD 48.00
+0.40 (0.84%)
Apr 29, 2026, 1:30 PM CST
Medigen Vaccine Biologics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -281.71 | -80.47 | -1,160 | -1,475 | 1,410 | Upgrade
|
| Depreciation & Amortization | 140.46 | 134.99 | 130 | 127.26 | 112.33 | Upgrade
|
| Other Amortization | 1.33 | 1.45 | 1.17 | 0.63 | 0.22 | Upgrade
|
| Loss (Gain) From Sale of Assets | 9.2 | -0.41 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -1.42 | 9.64 | 16.55 | 0.07 | Upgrade
|
| Stock-Based Compensation | 31.01 | 14.16 | 18.31 | 75.61 | 68.82 | Upgrade
|
| Other Operating Activities | -3.34 | 71.32 | -16.66 | 19.32 | -0.02 | Upgrade
|
| Change in Accounts Receivable | -11.99 | 31.08 | 45.29 | 445.79 | -635.73 | Upgrade
|
| Change in Inventory | 58.31 | -68.43 | 161.15 | 18.71 | -486.06 | Upgrade
|
| Change in Accounts Payable | -2.79 | -12.5 | -82.64 | 21.72 | 65.63 | Upgrade
|
| Change in Unearned Revenue | - | - | - | -111.41 | 111.41 | Upgrade
|
| Change in Other Net Operating Assets | 10.45 | -49.03 | 411.02 | -353.41 | -67.03 | Upgrade
|
| Operating Cash Flow | -49.09 | 40.75 | -482.56 | -1,214 | 579.89 | Upgrade
|
| Capital Expenditures | -50.64 | -34.3 | -38.69 | -139.17 | -133.63 | Upgrade
|
| Sale of Property, Plant & Equipment | 3.29 | 0.87 | - | - | 120 | Upgrade
|
| Sale (Purchase) of Intangibles | -1.14 | -0.68 | -2.27 | -1.17 | -1.34 | Upgrade
|
| Investment in Securities | 20 | 1,050 | 636.38 | -2,279 | -881.8 | Upgrade
|
| Other Investing Activities | -6.81 | 1.29 | 74.4 | 134.74 | -33.93 | Upgrade
|
| Investing Cash Flow | -35.3 | 1,018 | 669.83 | -2,285 | -930.69 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 30 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 1,755 | - | Upgrade
|
| Total Debt Issued | - | - | - | 1,755 | 30 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -30 | Upgrade
|
| Long-Term Debt Repaid | -39.19 | -1,740 | -11.78 | -11.56 | -1.93 | Upgrade
|
| Total Debt Repaid | -39.19 | -1,740 | -11.78 | -11.56 | -31.93 | Upgrade
|
| Net Debt Issued (Repaid) | -39.19 | -1,740 | -11.78 | 1,744 | -1.93 | Upgrade
|
| Issuance of Common Stock | - | 3.47 | 13.37 | 1,579 | 55.68 | Upgrade
|
| Other Financing Activities | - | - | - | - | -2.58 | Upgrade
|
| Financing Cash Flow | -39.19 | -1,736 | 1.59 | 3,323 | 51.18 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 0.11 | 0 | 0.35 | -0.11 | Upgrade
|
| Net Cash Flow | -123.58 | -677.51 | 188.87 | -175.44 | -299.73 | Upgrade
|
| Free Cash Flow | -99.72 | 6.46 | -521.25 | -1,353 | 446.26 | Upgrade
|
| Free Cash Flow Margin | -16.26% | 1.07% | -133.78% | -370.64% | 13.60% | Upgrade
|
| Free Cash Flow Per Share | -0.30 | 0.02 | -1.59 | -4.18 | 1.39 | Upgrade
|
| Cash Interest Paid | 8.66 | 7.72 | 7.32 | 7.53 | 6.02 | Upgrade
|
| Levered Free Cash Flow | -3.72 | -81.08 | -164.31 | -744.24 | -288.35 | Upgrade
|
| Unlevered Free Cash Flow | 1.79 | -69.27 | -140.83 | -727.43 | -284.59 | Upgrade
|
| Change in Working Capital | 53.98 | -98.88 | 534.82 | 21.39 | -1,012 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.